A single ascending dose study in healthy volunteers to assess the safety and PK of LY3372689, an inhibitor of O‐GlcNAcase (OGA) enzyme

• Published in: Alzheimer's & dementia Vol. 16
• Main Authors: Kielbasa, William, Phipps, Krista M, Tseng, James, Natanegara, Fanni, Cheng, Eden, Monk, Scott A., Bundgaard, Christoffer, Kevin, Donnelly B., Nuthall, Hugh Norman, McDonald, Nicholas, Lindsay‐Scott, Peter, Dreyfus, Nicolas, Hawk, Mai Khanh, Warner, Susan, Biglan, Kevin, Gilmore, Julie A., Zhang, Xiaoyu, Mergott, Dustin J., Lowe, Stephen L.
• Format: Journal Article
• Language: English
• Published: 01.12.2020

Background LY3372689, an O‐GlcNAcase (OGA) enzyme inhibitor, is being developed as a potential treatment for tauopathies, including Alzheimer’s disease. OGA inhibition is proposed to delay the progression of tau‐related diseases by slowing the accumulation of hyper‐phosphorylated, insoluble tau fila...